Business
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
REDWOOD CITY, Calif., February 24, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025.
About this update from Corcept Therapeutics Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":207,"url":"https://media.zenfs.com/en/business-wire.com/bae765e55c5809dcd433ce738c3960ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UEqn5hFAa5iUu5ZdWhfpUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bae765e55c5809dcd433ce738c3960ba","width":480,"height":207}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"2025 revenue of $761.4 million","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full year 2026 revenue guidance of $900 – $1,000 million","length":56,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"2025 net income of $99.7 million","length":32,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash and investments of $532.4 million at December 31, 2025","length":59,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":177,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., February 24, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025.","length":396,"tagName":"p"},{"type":"text","content":"Financial Results","length":17,"tagName":"p","attribs":{}},{"type":"text","content":""In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism’s true prevalence and the necessity of appropriate treatment. We had a record number of new prescriptions written for our medications and a record number of new prescribers in 2025, which translated to a 37 percent increase in the number of tablets sold compared to the prior year. We should have achieved higher growth but were not able to fully meet demand because of capacity constraints at our previous specialty pharmacy vendor. There were also operational disruptions in the fourth quarter as we transitioned our business to our new specialty pharmacy. This transition is now fully complete and Februar...